Schedule 13G ownership disclosure

CASI PHARMACEUTICALS INC

Ordinary Shares · CUSIP: G1933S101

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Panacea Venture Healthcare Fund II, L.P.

    Shares: 2,050,000 · Class: 13.2%

  • Panacea Venture Healthcare Fund II GP Company, Ltd.

    Shares: 2,050,000 · Class: 13.2%

  • Panacea Innovation Limited

    Shares: 2,050,000 · Class: 13.2%

  • James Huang

    Shares: 2,161,571 · Class: 13.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-097749
Form type
SCHEDULE 13G/A
Filer
CASI Pharmaceuticals, Inc.
CIK
CIK 1962738
Filed
Jul 23, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub